Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-K Annual Report
Period Ended: December 28, 2007
Business Overview: Greatbatch is a leading developer and manufacturer of critical components for implantable medical devices (IMDs) and electrochemical cells for commercial applications. The company operates in two segments: Implantable Medical Components (IMC) and Electrochem Commercial Power (ECP).
Strategic Activity: The fiscal year was defined by aggressive expansion through seven acquisitions (BIOMEC, Enpath, IntelliSensing, Quan Emerteq, EAC, Precimed, and DePuy Chaumont facility) to diversify into vascular, neurostimulation, orthopedic, and wireless sensor markets.
Key Financial Metrics
| Metric | 2007 | 2006 |
|---|---|---|
| Total Sales | $318.7 million | $271.1 million |
| Net Income | $15.1 million | $16.1 million |
| Diluted EPS | $0.67 | $0.73 |
| Operating Income | $20.0 million | $22.4 million |
| Operating Margin | 6.3% | 8.3% |
| Net Margin | 4.7% | 5.9% |
| Long-Term Debt | $241.2 million | $170.0 million |
| Cash & Short-Term Investments | $40.5 million | $142.6 million |
| Working Capital | $116.8 million | $199.1 million |
| Effective Tax Rate | 47.5% | 31.5% |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 18% year-over-year. Organic growth was 8%, while acquisitions contributed an additional 10% increase.
- Profitability Decline: Net income decreased 7% despite revenue growth, primarily due to significant non-recurring charges.
- Acquisition Charges: The company recorded $16.1 million in acquired in-process research and development (IPR&D) charges, primarily from the Enpath ($13.8 million) and BIOMEC ($2.3 million) acquisitions. These charges were immediately expensed.
- Debt Structure: Long-term debt increased by approximately $71 million due to the issuance of $80 million in new convertible notes and the exchange of existing notes. The company also entered a new $235 million revolving credit facility.
- Intangible Assets: Total intangible assets rose to $352.4 million (53% of total assets) due to acquisitions, increasing the risk of future impairment charges.
- Customer Concentration: Three customers (Boston Scientific, Medtronic, St. Jude Medical) accounted for 67% of total sales, consistent with the prior year.
Guidance, Outlook, and Risks
Outlook and Guidance
- 2008 Sales Forecast: Management expects full-year 2008 sales to range between $490 million and $530 million, driven by new acquisitions in therapy delivery and orthopedics.
- Market Growth: The company anticipates underlying Cardiac Rhythm Management (CRM) market growth of 5% in 2008.
- Cost Outlook: Cost of sales as a percentage of sales is expected to benefit from consolidation efforts, though a shift toward lower-margin products may offset some gains.
Management Commentary
Management views 2007 as a year of strategic transformation, shifting from a primary focus on CRM to a diversified global platform. The acquisitions were funded by cash on hand and new debt facilities. The company aims to reduce CRM market concentration from 80% to 50% of total sales by 2008.
Risks and Contingencies
- Customer Concentration: Heavy reliance on three major customers creates vulnerability if contracts are not renewed or volumes decrease.
- Acquisition Integration: Risks include the inability to integrate seven new companies, realize projected synergies, or manage increased debt levels.
- Intangible Asset Impairment: With intangible assets representing over half of total assets, any impairment could result in a large charge to earnings.
- Raw Material Costs: Prices for critical materials (lithium, tantalum, platinum) are volatile and rising, though some contracts allow for price pass-throughs.
- Legal Proceedings: The company is defending a patent infringement lawsuit regarding Enpath's FlowGuard introducer, with potential revenue impact of $3.0 million in 2007.
Investor Verification Checklist
- Acquisition Synergies: Verify the integration progress of the seven 2007/2008 acquisitions and whether projected cost savings are being realized.
- Customer Contracts: Confirm the status of supply agreements with the top three customers (Boston Scientific, Medtronic, St. Jude), which represent 67% of revenue.
- Debt Covenants: Review compliance with the new credit facility covenants, specifically the leverage ratio and adjusted EBITDA requirements, given the increased debt load.
- Intangible Asset Valuation: Assess the valuation assumptions for the $352.4 million in intangible assets and the potential for future impairment testing.
- IPR&D Commercialization: Monitor the development timeline for the acquired IPR&D projects (specifically Enpath and BIOMEC) to ensure they reach commercial feasibility and generate future revenue.
- Legal Exposure: Track the outcome of the patent infringement litigation involving the FlowGuard introducer.